Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 1215Triple Negative Breast Neoplasms 283Ovarian Neoplasms 262Carcinoma, Non-Small-Cell Lung 248Colorectal Neoplasms 189Pancreatic Neoplasms 168Stomach Neoplasms 164Neoplasm Metastasis 156Neoplasms 155Lung Neoplasms 144Prostatic Neoplasms 143Melanoma 132Carcinoma, Renal Cell 103Squamous Cell Carcinoma of Head and Neck 102Endometrial Neoplasms 99Head and Neck Neoplasms 88Colonic Neoplasms 82Urinary Bladder Neoplasms 79Uterine Cervical Neoplasms 77Esophageal Neoplasms 76Sarcoma 71Breast Neoplasms, Male 68Small Cell Lung Carcinoma 66Carcinoma, Hepatocellular 60Carcinoma, Ovarian Epithelial 58Kidney Neoplasms 47Carcinoma, Transitional Cell 41Rectal Neoplasms 35Fallopian Tube Neoplasms 34Liver Neoplasms 32

Interventions

pembrolizumab 1E7046 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Spinocerebellar Degenerations × Breast × Clear all
NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡